中国全科医学Issue(21)：2611-2614,4.DOI:10.3969/j.issn.1007-9572.2015.21.026
CT灌注成像对表皮生长因子受体酪氨酸激酶抑制剂治疗肺腺癌疗效的评估价值研究
Efficacy Evaluation of EGFR-TKI for Lung Adenocarcinoma by CT Perfusion Imaging
吕雅蕾 1刘巍 1时高峰 1刘风玲 1王玉栋 1冯莉 1王龙 1冯会 1韩晶1
作者信息
- 1. 050011河北省石家庄市，河北医科大学第四医院肿瘤内科，影像科
- 折叠
摘要
Abstract
Objective To investigate the evaluation value of CT perfusion imaging ( CTPI) for EGFR-TKI treatment for lung adenocarcinoma.Methods The study enrolled 32 patients with lung adenocarcinoma who underwent EGFR-TKI second-line treatment in the Department of Medical Oncology, the Department of Pneumology and the Department of Chest Surgery of the Fourth Hospital of Hebei Medical University from December 2011 to July 2013.According to efficacy, the patients were divided into remission group and non-remission group.The general data of the subjects were collected, including age, gender, performance status and clinical staging.Before treatment, and two months, four months and six months after treatment, comparison was made between the two groups on CTPI parameters ( BF, BV, MTT and PS) .Results The study assigned 11 patients to the remission group and 21 patients to the non-remission group.The age range was ( 55.2 ±3.2 ) for the remission group and (57.4 ±4.5) for the non-remission group, with no significant difference between them (t=1.437, P=0.163). The two groups were not significantly different in the proportion of male patients, ECOG score and clinical staging (P>0.05). Interaction effect was noted between BF, BV and time ( P <0.05 ); significant difference was noted between BF and BV at different time points ( P<0.05 ); BV was significantly different between the two groups ( P <0.05 ) .Four months and six months after treatment, BF decreased significantly in patients of the remission group, compared with two months before and after treatment ( P<0.05) .The remission group had lower BV two months, four months and six months after treatment than that before treatment (P<0.05), and it had lower BV four months after treatment than two months after treatment (P<0.05), while it had higher BV six months after treatment than four months after treatment ( P<0.05) .The non-remission group had higher BV four months and six months after treatment than before treatment, and it had higher BV six months after treatment than two months and four months after treatment.Conclusion CTPI can reflect quantitative tumor microvascular metabolic function of capillaries in tumors.It provides references for accurate efficacy evaluation of EGFR-TKI second -line treatment for lung adenocarcinoma.关键词
肺肿瘤/腺癌/表皮生长因子受体酪氨酸激酶抑制剂/灌注成像/治疗结果Key words
Lung neoplasms/Adenocarcinoma/EGFR-TKI/Perfusion imaging/Treatment outcome分类
医药卫生引用本文复制引用
吕雅蕾,刘巍,时高峰,刘风玲,王玉栋,冯莉,王龙,冯会,韩晶..CT灌注成像对表皮生长因子受体酪氨酸激酶抑制剂治疗肺腺癌疗效的评估价值研究[J].中国全科医学,2015,(21):2611-2614,4.
